NCT04443673 is a NA clinical trial of Glycine in COVID-19, sponsored by Instituto Nacional de Enfermedades Respiratorias.

Who is sponsoring NCT04443673?

NCT04443673 is sponsored by Instituto Nacional de Enfermedades Respiratorias.

What drugs are being tested in NCT04443673?

Interventions in NCT04443673: Glycine.

What condition does NCT04443673 study?

NCT04443673 studies COVID-19, SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, ARDS, Human, Pneumonia, Viral.

Is NCT04443673 still recruiting?

NCT04443673 is currently terminated. Last updated 4 August 2022.

Last reviewed 2022-08-04 · How we verify

NCT04443673

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glycine Supplement for Severe COVID-19

Terminated NA Last updated 4 August 2022

What this trial tests

NA trial testing Glycine in COVID-19 in 59 participants. Terminated before completion.

Timeline

15 June 2020

Primary endpoint
14 June 2021

14 June 2021

Quick facts

Lead sponsor	Instituto Nacional de Enfermedades Respiratorias
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	15 June 2020
Primary completion	14 June 2021
Estimated completion	14 June 2021
Sites	1 location across Mexico

Drugs / interventions tested

Glycine (GLYCINE) — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
SARS-CoV Infection — all drugs for SARS-CoV Infection →
SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →
SARS Pneumonia — all drugs for SARS Pneumonia →

Sponsor

Instituto Nacional de Enfermedades Respiratorias — full company profile →

Who can join

Eligibility, any sex, with COVID-19 or SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will explore whether a daily supplement of glycine, a substance that has antiinflammatory, cytoprotective, and endothelium-protecting effects, can improve mortality, as well as clinical and biochemical parameters, in patients with severe COVID-19 who initiate mechanical ventilatory support.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics.
Pokharel MD, Garcia-Flores A, Marciano D, Franco MC, et al · · 2024 · cited 73× · PMID 38295575 · DOI 10.1016/j.redox.2024.103049
Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients.
Schmelter F, Föh B, Mallagaray A, Rahmöller J, et al · · 2021 · cited 37× · PMID 34938772 · DOI 10.3389/fmolb.2021.737039
A Comprehensive Summary of the Knowledge on COVID-19 Treatment.
Peng Y, Tao H, Satyanarayanan SK, Jin K, et al · · 2021 · cited 18× · PMID 33532135 · DOI 10.14336/ad.2020.1124
Metabolic markers distinguish COVID-19 from other intensive care patients and show potential to stratify for disease risk
Schmelter F, Foeh B, Mallagaray A, Rahmoeller J, et al · · 2021 · cited 3× · DOI 10.1101/2021.01.13.21249645
A physiological link for psychiatric symptoms in COVID-19: Role of amino acid deficiency.
Soni VK, Sharma K, Mehta A, Ratre YK, et al · · 2020 · cited 3× · PMID 33264844 · DOI 10.1016/j.ajp.2020.102426
Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial.
Vargas MH, Chávez J, Del-Razo-Rodríguez R, Muñoz-Perea C, et al · · 2024 · cited 2× · PMID 38773199 · DOI 10.1038/s41598-024-62321-7
Glycine promotes cardiomyocyte proliferation and heart regeneration via the GCN2/AKT signaling axis.
Wang F, Zhang X, Tang Y, He Y, et al · · 2026 · PMID 42094615 · DOI 10.7150/thno.127992
Lower Serum Magnesium Is Associated with Mortality in Severe COVID-19: A Secondary Analysis of a Randomized Trial.
Vargas MH, Chávez J, Del-Razo-Rodríguez R, Muñoz-Perea C, et al · · 2025 · PMID 40234280 · DOI 10.1007/s12011-025-04619-9

Verify or expand the search:

Other trials of Glycine

Trials testing the same drug.

NCT04740580 — Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease · EARLY_PHASE1 · recruiting
NCT04658134 — Glycine "Deficiency" and the Kinetics of Acylglycine in Morbid Obesity · NA · unknown
NCT04703036 — Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19 · EARLY_PHASE1 · terminated
NCT03493178 — Glutathione in Mild Cognitive Impairment · EARLY_PHASE1 · active not recruiting
NCT03180775 — Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity · NA · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Instituto Nacional de Enfermedades Respiratorias trials

Trials by the same sponsor.

NCT06471101 — Applying Artificial Intelligence to Identify Subphenotypes of Acute Kidney Injury in Mexican Patients With Severe COVID- · completed
NCT06691321 — Caspofungin for Pneumocystis Pneumonia in PLWHIV. · recruiting
NCT04517630 — Renal Biomarkers in AKI and COVID-19 · completed
NCT06444893 — Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients · completed
NCT03627481 — Sleep Quality After Nasosinusal Surgery in AERD Patients · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04443673 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Enfermedades Respiratorias
Last refreshed: 4 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04443673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing